Watchlist

Watchlist
Agios Pharmaceuticals, Inc. (AGIO)
Agios Pharmaceuticals, Inc. (AGIO)
3 Things In Biotech You Should Learn Today: January 10, 2018
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. And I announced this yesterday via blog post, but I wanted to let you know officially once ag…
Agios Gears Up Pipeline To Create Future Value
Agios ( AGIO ) became a commercial stage biotech pharmaceutical company in August 2017 when the FDA approved Idhifa for AML (acute myeloid leukemia) with certain specific biomarkers. Celgene ( CELG ) owns Idhifa, with Agios to receive royalties. Agios has other collaborations with Celgene, p…
Agios Pharmaceuticals (AGIO) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more …
Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc. (Agios or the Company) (NASDAQ:AGIO) into potential breaches of fiduciary duty by the Companys Board of Directors (t…
Goldman bullish on biopharma in 2018
In a note, Goldman Sachs analyst Salveen Richter says M&A activity in the biopharma space should pick up this year. Likely buyers include Celgene ( CELG -1% ), Pfizer ( PFE -0.2% ), Merck ( MRK +0.2% ) and J&J ( JNJ ), AbbVie ( ABBV -0.5% ), Amgen ( AMGN ), AstraZeneca ( AZN …
Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results
Analysis of top Seeking Alpha coverage: Achaogen Today we will discuss the latest update from Achaogen ( AKAO ). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market….
Your Daily Pharma Scoop: Portola BLA Review Process Delayed, DelMar Soars, Alexion Gets Nod For Soliris In Japan
Analysis of top Seeking Alpha coverage: Portola Today we will discuss the implications of the delay in the review of Portolas ( PTLA ) AndexXa BLA. The news sent PTLA shares down more than 10% on Tuesday. Portola closed 10.68% lower on Tuesday at $49. Despite the sell-off on Tu…
Agios submits NDA for Ivosidenib for the treatment of relapsed/refractory AML and an IDH1 mutation
Agios Pharmaceuticals (NASDAQ: AGIO ) submits a New Drug Application (NDA) to the FDA for ivosidenib (AG-120), an investigational oral treatment for patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-1 (IDH1) mutation. More news on: Ag…
Agios Pharmaceuticals: Updates To Thesis And A Look Toward 2018
Shares of Agios Pharmaceuticals ( AGIO ) rose by as much as 50% since I called the stock "another core buy in biotech worth picking up " back in April. Currently the stock has pulled back significantly and could be offering readers a buying opportunity going into 2018. AGIO data by YCh…
Your Daily Pharma Scoop: Right Time To Buy Regeneron, Eli Lilly Gives Guidance, Bluebird Announces Offering
Content Analysis of coverage: REGN Stocks in the news: LLY, SNY, BLUE Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Trade Idea of the Day (for TPT subscribers only) Subscriber Questions & An…
Agios Pharma's ivosidenib shows positive effect in early-stage AML study; shares ahead 3% after hours
Results from a Phase 1 dose-escalation and expansion study assessing Agios Pharmaceuticals' (NASDAQ: AGIO ) ivosidenib (AG-120) in patients with relapsed/refractory acute myeloid leukemia (AML) with a genetic mutation called IDH1 showed a treatment benefit. The data were presented at ASH …
Agios Pharmaceuticals, Inc. (AGIO)